- Home
- TFC vs REGN Comparison
TFC vs REGN Comparison
Compare TFC & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TFC
- REGN
- Stock Information
- Founded
- TFC 1872
- REGN 1988
- Country
- TFC United States
- REGN United States
- Employees
- TFC N/A
- REGN N/A
- Industry
- TFC Major Banks
- REGN Biotechnology: Pharmaceutical Preparations
- Sector
- TFC Finance
- REGN Health Care
- Exchange
- TFC Nasdaq
- REGN Nasdaq
- Market Cap
- TFC 52.4B
- REGN 59.5B
- IPO Year
- TFC N/A
- REGN 1991
- Fundamental
- Price
- TFC $43.96
- REGN $600.74
- Analyst Decision
- TFC Buy
- REGN Buy
- Analyst Count
- TFC 15
- REGN 21
- Target Price
- TFC $49.21
- REGN $808.43
- AVG Volume (30 Days)
- TFC 6.1M
- REGN 972.9K
- Earning Date
- TFC 10-16-2025
- REGN 08-01-2025
- Dividend Yield
- TFC 4.69%
- REGN 0.60%
- EPS Growth
- TFC N/A
- REGN 5.03
- EPS
- TFC 3.70
- REGN 39.67
- Revenue
- TFC $18,166,000,000.00
- REGN $14,214,200,000.00
- Revenue This Year
- TFC $81.42
- REGN N/A
- Revenue Next Year
- TFC $4.75
- REGN $6.65
- P/E Ratio
- TFC $12.00
- REGN $14.90
- Revenue Growth
- TFC 67.21
- REGN 5.38
- 52 Week Low
- TFC $33.56
- REGN $476.49
- 52 Week High
- TFC $49.06
- REGN $1,211.20
- Technical
- Relative Strength Index (RSI)
- TFC 48.70
- REGN 64.02
- Support Level
- TFC $43.99
- REGN $570.39
- Resistance Level
- TFC $44.74
- REGN $596.92
- Average True Range (ATR)
- TFC 0.74
- REGN 15.19
- MACD
- TFC -0.02
- REGN 2.77
- Stochastic Oscillator
- TFC 54.51
- REGN 93.18
About TFC Truist Financial Corporation
Based in Charlotte, North Carolina, Truist is the combination of BB&T and SunTrust. Truist is a regional bank with a presence primarily in the Southeastern United States. In addition to commercial banking, retail banking, and investment banking operations, the company operates several nonbank segments.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).